A Study to Evaluate the Safety and Efficacy of Obinutuzumab Compared With Placebo in Participants With Lupus Nephritis (LN)

NCT02550652 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

126

Enrollment

INDUSTRY

Sponsor class

Conditions

Lupus Nephritis

Interventions

DRUG: Mycophenolate Mofetil/Mycophenolic Acid
DRUG: Obinutuzumab
OTHER: Placebo
DRUG: Methylprednisolone
DRUG: Prednisone

Sponsor

Hoffmann-La Roche